Mode
Text Size
Log in / Sign up

MDS patients have 6.2 times higher cardiovascular disease prevalence than the general populationPeople with myelodysplastic syndrome face higher risk of heart disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that MDS patients have a 6.2 times higher risk of cardiovascular disease and high rates of multimorbidity.

This meta-analysis evaluated the prevalence of comorbidities among a large cohort of 71,400 patients diagnosed with myelodysplastic syndrome (MDS). The study aimed to quantify the burden of noncommunicable diseases in this specific patient population compared to the general population to better inform clinical management and multidisciplinary care strategies.

The primary outcome measured was the prevalence of comorbidities among patients with MDS. The analysis revealed that cardiovascular disease prevalence was 6.2 times greater in the MDS population than in the general population. Furthermore, the study identified a significant difference in multimorbidity prevalence, which was 79.1% in the MDS group compared to 63.4% in the general population (p <.0001). These figures indicate a substantial burden of concurrent chronic conditions in patients with MDS.

Secondary outcomes included specific prevalence rates for various chronic conditions. Heart failure prevalence was reported between 10.4% and 18.6% in the MDS cohort. Additionally, the study assessed the prevalence of chronic kidney disease and chronic liver disease, as well as the prevalence of solid tumors. While the specific percentages for kidney and liver disease were not reported as individual figures, the overall prevalence of multimorbidity within the MDS population was noted at 35%.

Regarding mortality, the analysis examined the risk associated with multimorbidity. Patients with multimorbidity were found to be twice as likely to die (2.0) compared to those without. This finding highlights the significant impact that concurrent chronic conditions have on survival outcomes for patients with MDS. The association between MDS and noncommunicable diseases was noted to remain strong across both high-income and low-income regions.

Safety and tolerability data, including specific adverse event rates or discontinuation rates, were not reported in this meta-analysis. Methodological limitations were not reported. However, the findings underscore a significant clinical challenge: the high prevalence of comorbidities, particularly cardiovascular issues, necessitates a holistic and patient-centered approach to care.

These results highlight the necessity of a multidisciplinary team to manage the complex needs of MDS patients. Because the prevalence of cardiovascular disease is 6.2 times higher than the general population, early screening and integrated management of heart failure and other chronic conditions are essential. The high rate of multimorbidity (79.1%) suggests that clinical management must go beyond the primary hematologic condition to address the systemic health of the patient.

Several questions remain regarding the specific drivers of these comorbidities and the specific impact of chronic kidney disease or liver disease on MDS progression. While the association between MDS and noncommunicable diseases is strong, more granular data on the specific management of these comorbidities within the MDS population would be beneficial for clinical practice. The findings suggest that a multidisciplinary approach is required to address the common chronic diseases found in these patients.

How this fits prior evidence

How this fits prior evidence: This meta-analysis addresses a gap in understanding the systemic burden of disease in patients with myelodysplastic syndrome (MDS). While previous evidence has focused on specific complications in chronic kidney disease (CKD), such as a 47.0% prevalence of protein-energy wasting or the impact of dysregulated tryptophan metabolism on cognition, this study highlights the high prevalence of heart failure (10.4% to 18.6%) and cardiovascular disease (6.2 times higher than the general population) in the MDS population.

Living with myelodysplastic syndrome (MDS) is already a significant challenge for many patients. MDS is a type of blood cancer where the bone marrow does not produce enough healthy blood cells. However, new data shows that the struggle for these patients often involves more than just their primary diagnosis. People with MDS are much more likely to deal with other serious, long-term health problems at the same time, a situation doctors call multimorbidity. This means that managing one illness often comes with the added weight of managing several others simultaneously.

To understand the scope of this issue, researchers looked at data from over 71,000 people with MDS. They compared these patients to the general population to see how often other chronic diseases appeared. The results showed a striking difference in heart health. Patients with MDS were found to have a much higher rate of heart failure, with between 10.4% and 18.6% of those patients affected. Even more striking, the prevalence of cardiovascular disease in this group was over six times higher than what is seen in the general public.

Beyond heart issues, the study looked at other conditions like chronic kidney disease and chronic liver disease. The data confirmed that patients with MDS are more likely to have multiple chronic conditions compared to the general population. Specifically, about 35% of those with MDS had multiple conditions. When patients face these multiple illnesses at once, the stakes become even higher. The study found that people with multiple conditions were twice as likely to die compared to those with only one condition.

It is important to remember that this is a large-scale review of existing data, not a new clinical trial for a specific drug. While the numbers show a strong link between MDS and heart issues, they do not tell us exactly why this happens or how to treat it immediately. The findings are consistent across different regions, meaning this is a widespread issue for patients everywhere.

For patients right now, this information highlights the need for a different kind of care. Instead of only focusing on the blood disorder, doctors and patients can work together to take a more complete look at overall health. This means a team of different specialists can help manage heart, kidney, and liver health alongside MDS treatment. The goal is to provide a more complete, patient-centered approach to care that addresses the whole person, not just one disease.

What this means for you:
Patients with MDS have much higher rates of heart failure and other chronic illnesses than the general population.

Study Details

Study typeMeta analysis
Sample sizen = 71,400
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
The authors performed a systematic review and meta-analysis to estimate the prevalence of comorbidities among patients with myelodysplastic syndrome (MDS) by pooling results from 28 studies and 71,400 patients. In conducting this research, the authors observed that individuals with MDS have a high rate of cardiovascular disease that is 6.2 times greater than that in the general population. A remarkably high prevalence of heart failure (between 10.4% and 18.6%) was observed, indicating that heart failure is a major issue that warrants urgent attention in MDS. The prevalence of chronic kidney disease, chronic liver disease, and solid tumors was also higher in patients with MDS. The results of this analysis indicate a much higher prevalence of multimorbidity in patients who have MDS compared with the general population (79.1% vs. 63.4%; p < .0001). Furthermore, the data demonstrate that the association between MDS and noncommunicable diseases remains strong in both high-income and low-income regions, the comorbidity burden increases with higher scores on the revised International Prognostic Scoring System, patients with multimorbidity are twice as likely to die as those without multimorbidity, and a high burden of comorbidities emerges as a common problem in MDS, occurring in 35% of patients. These findings suggest that a focus on multimorbidity and a holistic, multidisciplinary, and patient-centered approach to address the challenge of common chronic diseases could significantly improve outcomes for patients with MDS.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.